Namaxir (Methotrexate)

Methotrexate, the active ingredient in Namaxir, is an antimetabolite presented as an injectable for subcutaneous use. It is employed to manage rheumatoid arthritis, severe psoriasis, and certain malignancies such as leukemia and lymphoma in adult patients.

GNH USA supplies Namaxir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows EU Good Manufacturing Practice, provides full regulatory dossiers, and supports import logistics for qualified healthcare institutions.

Methotrexate is an antimetabolite used in several immune‑mediated and oncologic conditions.

Rheumatoid arthritis: reduces joint inflammation, pain, and swelling while slowing disease progression, thereby improving functional ability and quality of life. Psoriasis: decreases abnormal skin cell proliferation and local inflammation, resulting in clearance or significant reduction of psoriatic plaques. Leukemia and lymphoma: interferes with rapidly dividing cancer cells, contributing to remission when used in combination chemotherapy protocols.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Fatigue or malaise - Mouth sores (stomatitis) - Elevated liver enzymes

Serious or Rare Side Effects: - Severe liver toxicity or fibrosis - Pulmonary fibrosis or interstitial pneumonitis - Bone marrow suppression leading to severe infection or anemia

When using methotrexate, careful monitoring and patient education are essential.

Monitor blood counts: perform regular complete blood count tests to detect myelosuppression early. Assess liver function: conduct periodic liver enzyme tests and avoid use in pre‑existing hepatic disease. Evaluate renal function: adjust dosing or avoid if creatinine clearance is markedly reduced. Avoid use in pregnancy: methotrexate is teratogenic and contraindicated for women of childbearing potential unless effective contraception is used. Counsel on infection risk: advise patients to report signs of infection promptly and limit exposure to live vaccines. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Methotrexate interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - NSAIDs (e.g., ibuprofen, naproxen): increase methotrexate toxicity by reducing renal clearance. - Trimethoprim‑sulfamethoxazole: potentiates myelosuppression and hepatotoxicity. - Live vaccines: may cause uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine or other immunosuppressants: additive bone marrow suppression requires close laboratory monitoring. - Proton pump inhibitors (e.g., omeprazole): may modestly increase methotrexate plasma levels; monitor renal function.